
    
      Up to 30 evaluable patients from the CASIMAS study will be enrolled. Catumaxomab will be
      infused intraperitoneally with 3hour constant-rate infusions 4 times within 11 days with
      ascending dosages (10 - 20 - 50 - 150 Âµg).
    
  